GlobeNewsWire · NET · November 5, 2026

Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs

Get the app for more

Explore stock news, insights and company research.